Orphazyme may face class action suit from US investors
A potential lawsuit in the US may be on the cards for Copenhagen-based biotech company Orphazyme, according to the company's H1 report. This is happening after several disappointments for the company over the past half-year, though the CEO and CFO say the suit is unfounded.
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
Copehagen-based biotech company Orphazyme may be facing legal proceedings in the US, as lawyers are hunting for investors to join a possible class action suit.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.